Anti-Mouse FOXP3 – Purified (PhenoCyler-Fusion (CODEX)® Ready)

Clone MF-14 has been validated for use on PhenoCycler® using [Mouse/Human] [Tissue] [Tissue Type either FFPE or FF] tissue.

This purified antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4.

This antibody is stable for at least one week when stored at 2-8°C. For long term storage, aliquot in working volumes without diluting and store at -20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.

MF-14 activity is directed against mouse FOXP3.

FOXP3 is a unique marker of CD4⁺CD25⁺ regulatory T cells, distinguishing them from activated CD4⁺CD25⁻ T cells.

FOXP3 is a transcription factor¹ required for development of CD4⁺CD25⁺ regulatory T cells (Treg) that does not affect CD4⁺CD25⁻ T cell proliferation². Treg cells expressing FOXP3 play a critical role in the maintenance of immune homeostasis and prevention of autoimmunity¹. FOXP3 promotes the generation of Tregs, represses cytokine expression in primary CD4⁺ T cells, and suppresses the transcriptional activities of NFAT and NF-κB³. FOXP3 also inhibits basal activation of PKC-θ, IκB kinase β (IKKβ), and TNF-α stimulation of NF-κB. Depletion of FOXP3⁺CD4⁺ Treg cells and/or loss of function mutations of FOXP3 results in severe autoimmunity, allergy, immunopathology as well as cancer immunity¹.

FOXP3 is predominantly expressed in CD25⁺CD4⁺ Tregs in the thymus and periphery^2,4, and abundance increases upon in vitro activation of CD4⁺CD25⁺ Tregs². Additionally, expression of FOXP3 in naïve T cells can convert these cells to a Treg phenotype⁴. FOXP3 is virtually undetectable in resting and activated CD4⁺CD25⁻ T cells².

FOXP3 represents a more specific marker for CD4⁺ Tregs than e.g., CD25, CD45RB, CTLA-4, and GITR which do not discriminate between Tregs and activated, effector, or memory T cells⁴.

1. Wing JB, Tanaka A, Sakaguchi S. Immunity. 50(2):302-316. 2019.
2. Fontenot JD, Gavin MA, Rudensky AY. Nat Immunol. 4(4):330-336. 2003.
3. Bettelli E, Dastrange M, Oukka M. Proc Natl Acad Sci U S A. 2005;102(14):5138-5143.
4. Hori S, Nomura T, Sakaguchi S. Science. 299(5609):1057-1061. 2003.
5. Barber A, Rynda A, Sentman CL. J Immunol. 183(11):6939-6947. 2009.
6. Burzynski LC, Humphry M, Pyrillou K, et al. Immunity. 50(4):1033-1042.e6. 2019.
7. Nakashima H, Hamaguchi Y, Watanabe R, et al. J Immunol. 184(9):4637-4645. 2010.
8. Fallarino F, Volpi C, Zelante T, et al. J Immunol. 183(10):6303-6312. 2009.